GlaxoSmithKline has named Dr. Jingwu Zang to run a major new R&D center in Shanghai which will focus on developing a new generation of neurodegenerative drugs. Glaxo plans to concentrate all of its research on such diseases as Parkinson's and Alzheimer's at the center, taking its drugs from target identification through late-stage trials. The center is designed to grow into one of the largest research efforts within Glaxo's multinational operations.
"We intend to be part of a future in which the phrase 'discovered in China' is heard as often as 'made in China' is heard today," said Glaxo research chief Moncef Slaoui.
- check out the release
China says former drug czar accepted bribes. Report
Bridge garners $35M to expand China operations. Report